Currently out of the existing stock ratings of Kevin Kedra, 7 are a BUY (46.67%), 6 are a HOLD (40%), 2 are a SELL (13.33%).

Kevin Kedra

Work Performance Price Targets & Ratings Chart

Analyst Kevin Kedra, carries an average stock price target met ratio of 90% that have a potential upside of 60.04% achieved within 615 days.

Kevin Kedra’s has documented 29 price targets and ratings displayed on 6 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ELAN, Elanco Animal Health at 17-Jun-2021.

Wall Street Analyst Kevin Kedra

Analyst best performing recommendations are on LXRX (LEXICON PHARMACEUTICALS).
The best stock recommendation documented was for LXRX (LEXICON PHARMACEUTICALS) at 9/11/2019. The price target of $3 was fulfilled within 7 days with a profit of $0.8 (36.36%) receiving and performance score of 51.95.

Average potential price target upside

of $7.43 (61.55%) on COLL (COLLEGIUM PHARMACEUTICAL).
of $70.6 (101.73%) on TTPH (TETRAPHASE PHARMACEUTICALS).
of $0.8 (36.36%) on LXRX (LEXICON PHARMACEUTICALS).

LXRX Lexicon Pharmaceuticals ELAN Elanco Animal Health TTPH Tetraphase Pharmaceuticals PAHC Phibro Animal Health COLL Collegium Pharmaceutical NBRV Nabriva Therapeutics AG

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Joseph Pantginis (HC WAINWRIGHT)